Canaccord analyst Gary Nachman raised the firm’s price target on AbbVie (ABBV) to $265 from $262 and keeps a Buy rating on the shares. The firm said ABBV delivered upside in 1Q across all key franchises and was led by Immunology and Neuro as the results showed good momentum for key grwoth drivers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV: